Sun Pharmaceutical Industries and its subsidiaries have secured a significant legal victory in their ongoing antitrust litigation in the United States. According to reports from Business Standard, the United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the Company and its subsidiaries. The appellate court has also affirmed the District Court's orders denying class certification as to the plaintiffs. As per Sun Pharma's regulatory disclosure, the matter is now considered substantially closed, subject to any further remedies that may be available to the plaintiffs under applicable law. The ruling is particularly significant because the litigation had remained a long-standing legal overhang following Sun Pharma's acquisition of Ranbaxy in 2014.
The antitrust litigation stems from a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin). As reported by Business Standard, plaintiffs had alleged that the settlement unlawfully delayed generic competition for Lipitor and that absent the unlawful settlement, Lipitor would have entered the market earlier than it did. The matter has been disclosed from time to time in the Company's financial statements throughout the legal proceedings. According to Sun Pharma's regulatory filing, the litigation centered on a 2008 patent settlement agreement between Sun Pharma and Pfizer, with plaintiffs alleging that this settlement unlawfully delayed the entry of generic competition for Lipitor into the US market.
This decision represents a significant favourable development for the Company and its subsidiaries in the matter, according to Business Standard reports. The litigation has been substantially brought to a close, subject to any further remedies that may be available to the plaintiffs under applicable law. The appellate court's affirmation of the lower court's summary judgment provides finality to the legal proceedings that have been ongoing for several years. As per Sun Pharma's regulatory disclosure, this outcome represents a favourable development for the company, removing a material legal overhang associated with the case. The Third Circuit's decision effectively removes the principal claims against Sun Pharma in this matter, providing final resolution to the long-standing litigation.
Despite the legal victory, Sun Pharma's stock has declined, shedding 0.58% to currently trade at ₹1,913.70 on the BSE. However, the company reported strong financial results for Q1 FY27, with consolidated net profit jumping 27.04% to ₹2,894.79 crore compared to ₹2,278.63 crore in the corresponding quarter last year. Revenue from sales also showed robust growth, climbing 10.14% year-on-year to ₹15,183.55 crore in Q1 FY27. Sun Pharma is engaged in manufacturing, developing and marketing branded and generic formulations globally, with the company being the largest pharmaceutical company in India.
